UroGen Pharma (NASDAQ:URGN) Announces Earnings Results

UroGen Pharma (NASDAQ:URGN) issued its earnings results on Monday. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11), Zacks reports.

UroGen Pharma Price Performance

UroGen Pharma stock opened at $9.92 on Tuesday. The company’s 50 day simple moving average is $10.44 and its 200-day simple moving average is $11.72. The company has a market capitalization of $232.66 million, a price-to-earnings ratio of -3.15 and a beta of 1.12. UroGen Pharma has a 1 year low of $9.03 and a 1 year high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $64.00 target price on shares of UroGen Pharma in a research note on Tuesday, February 25th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research note on Monday. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $40.00.

Insider Activity

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now directly owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.